You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Unraveling the Complexity of Severe Asthma Treatment

  • Authors: Ronald Balkissoon, MD, MSc, DIH, FRCPC; Monica Kraft, MD; Flavia Cecilia Lega Hoyte, MD
  • CME Released: 11/30/2022
  • Valid for credit through: 11/30/2023, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

Pulmonologists, allergists, nurse practitioners, and physician assistants in those specialties.

Severe asthma is a heterogeneous condition with many clinical manifestations and variations in endotype, phenotype, and biomarkers/cytokines. New and emerging therapies targeting epithelial alarmins may improve outcomes for a broad range of patients.

Upon completion of this activity, participants will:

  1. Describe the role of the airway epithelium in asthma.
  2. Define the epithelial alarmins and their impact on T2 and non-T2 airway inflammation, remodeling, and hyper responsiveness in severe asthma.
  3. Evaluate the results of clinical trials of current and emerging therapies that target the epithelial alarmins in severe asthma.
  4. Match clinical characteristics and phenotypes to treatment targets.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.

Unlabeled and Investigational Usage

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Disclaimer Statement

National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.


Moderator

  • Ronald Balkissoon, MD, MSc, DIH, FRCPC

    Pulmonary Consultant
    Department of Medicine
    National Jewish Health
    Denver, Colorado

    Disclosures

    Ronald Balkissoon, MD, MSc, DIH, FRCPC, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca Pharmaceuticals; Genentech; GlaxoSmithKline; Regeneron; Sanofi
    Speaker or member of speakers bureau for: AstraZeneca Pharmaceuticals; Genentech

Faculty

  • Flavia Cecilia Lega Hoyte, MD

    Associate Professor of Medicine
    Fellowship Training Program Director
    Division of Allergy and Immunology
    National Jewish Health
    University of Colorado
    Denver, Colorado

    Disclosures

    Flavia Cecilia Lega Hoyte, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca Pharmaceuticals; Genentech
    Speaker or member of speakers bureau for: AstraZeneca Pharmaceuticals; GlaxoSmithKline (former)
    Owns stock (publicly traded) in: Amgen
    Investigator for: AstraZeneca Pharmaceuticals; Genentech; Regeneron; Sanofi; TEVA Pharmaceuticals

  • Monica Kraft, MD

    System Chair
    Samuel Bronfman Department of Medicine
    Icahn School of Medicine at Mount Sinai
    Mount Sinai Health System
    New York, New York

    Disclosures

    Monica Kraft, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca Pharmaceuticals; Chiesi Pharmaceuticals; Sanofi Regeneron (all former)
    Speaker or member of speakers bureau for: Chiesi Pharmaceuticals (former)

Additional Planners/Reviewers

  • Harold Nelson, MD, has the following relevant financial relationships:
    • Consultant: ALK
    • Data Safety Monitoring Board: AstraZeneca Pharmaceuticals
  • Zulma Yunt, MD, has no relevant financial relationships.
  • Meghan Brenner, MA, has no relevant financial relationships.
  • Elyce Bowron, MEd, has no relevant financial relationships.
  • Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    National Jewish Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Unraveling the Complexity of Severe Asthma Treatment

Authors: Ronald Balkissoon, MD, MSc, DIH, FRCPC; Monica Kraft, MD; Flavia Cecilia Lega Hoyte, MDFaculty and Disclosures

CME Released: 11/30/2022

Valid for credit through: 11/30/2023, 11:59 PM EST

processing....

Assessment Survey

  • Print